A team from ULiège, in collaboration with the GIGA-Cardiovascular Sciences and the Cardiology Department of the Academic hospital of Medical University of Liège, demonstrates that a regularly prescribed medication against coronary heart disease, coronary syndrome and infarction is also a powerful antibiotic.
Researchers’work has revealed that the antiplatelet drug Ticagrelor (marketed as Brilique® in Belgium) is capable of killing bacteria resistant to conventional antibiotics with a much faster action. Ticagrelor helps prevent cardiovascular diseases, such as heart attacks and strokes; it is one of the most commonly prescribed drugs in the world.
This discovery represents a major breakthrough against infections caused by antibiotic resistant super-bacteria commonly used in hospitals. These bacteria, which are primarily responsible for the infection of medical implants, prostheses and sepsis, pose a huge threat to human health worldwide. Their current antibiotic resistance is leading to increased mortality and increased health care costs.
Researchers in Liège can now develop new therapeutic strategies based on the Ticagrelor mode of action. Their researches are likely to be crucial in the fight against bacterial infections and antibiotic resistance worldwide.